Catatan sumber primer
PenentuPersetujuan FDA
Eton Pharmaceuticals: FDA menyetujui DESMODA (desmopressin) Oral Solution
FDA menyetujui NDA untuk DESMODA (desmopressin acetate) Oral Solution pada 25 Februari 2026. Persetujuan mencakup terapi pengganti antidiuretik untuk central diabetes insipidus/AVP-D pada pasien segala usia. Produk ini kini telah disetujui untuk peluncuran komersial di AS.
Fakta utama
- Diajukan
- 25 Feb 2026, 19.18
- Peristiwa
- Persetujuan FDA
- Arah
- Positif
- Perusahaan
ETONEton Pharmaceuticals- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
eton20260223_8k.htm false 0001710340 0001710340 2026-02-25 2026-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File Number) Identification Number) 21925 W. Field Parkway, Suite 235 Deer Park , Illinois 60010 -7278 (Address of principal executive offices) (Zip code) ( 847 ) 787-7361 (Registrant ’ s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simul